Cannabis,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 16, 2024
Objective:
Rates
of
chronic
pain
are
higher
among
rural
versus
urban
individuals
and
experience
levels
socioeconomic
disadvantage,
poor
or
no
health
insurance
coverage,
unmet
treatment
need.
Medical
cannabis
is
legal
in
Oklahoma.
With
40%
Oklahoma’s
population
living
areas,
nearly
17%
uninsured,
the
medical
legalization
may
present
as
an
accessible
relatively
low-cost
alternative
treatment,
particularly
for
those
with
pain.
This
study
investigated
differences
use
by
(vs.
urban)
status
met)
need
adults
without
Method:
To
be
eligible,
participants
had
to
18
years
older,
reside
Oklahoma,
able
read
write
English-language
surveys.
Results:
The
sample
(N
=
3622)
was
primarily
made
up
non-Hispanic
White
(70.4%)
females
(53.8%)
their
early
middle
age
(M
41.80,
SD
16.88),
employed
full-time
part-time
(53.8%),
some
college/technical
school
(37.2%)
a
bachelor’s
degree
(28.5%).
Nearly
one-fifth
(18.2%)
endorsed
pain,
were
eight
times
more
likely
report
past
30-day
use.
No
difference
detected
when
only
rurality
residence)
examined.
Among
who
dwelling
reported
almost
two
use,
compared
Conclusions:
In
areas
benefit
from
increasing
access
well
education
on
harm
reduction
strategies
inform
healthcare
decision-making.
Journal of Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
42(13), P. 1575 - 1593
Published: March 13, 2024
To
guide
clinicians,
adults
with
cancer,
caregivers,
researchers,
and
oncology
institutions
on
the
medical
use
of
cannabis
cannabinoids,
including
synthetic
cannabinoids
herbal
derivatives;
single,
purified
cannabinoids;
combinations
ingredients;
full-spectrum
cannabis.
JNCI Monographs,
Journal Year:
2024,
Volume and Issue:
2024(66), P. 202 - 217
Published: Aug. 1, 2024
Abstract
Background
The
legal
climate
for
cannabis
use
has
dramatically
changed
with
an
increasing
number
of
states
passing
legislation
legalizing
access
medical
and
recreational
use.
Among
cancer
patients,
is
often
used
to
ameliorate
adverse
effects
treatment.
Data
are
limited
on
the
extent
type
among
patients
during
treatment
perceived
benefits
harms.
This
multicenter
survey
was
conducted
assess
residing
in
varied
cannabis.
Methods
A
total
12
NCI-Designated
Cancer
Centers,
across
cannabis-access
status,
surveys
a
core
questionnaire
recently
diagnosed
patients.
were
collected
between
September
2021
August
2023
pooled
centers.
Frequencies
95%
confidence
intervals
measures
calculated,
weighted
estimates
presented
10
sites
that
drew
probability
samples.
Results
Overall
reported
since
diagnosis
respondents
32.9%
(weighted),
which
slightly
by
state
legalization
status.
most
common
pain,
sleep,
stress
anxiety,
side
effects.
Reported
risks
less
included
inability
drive,
difficulty
concentrating,
lung
damage,
addiction,
impact
employment.
majority
feeling
comfortable
speaking
health-care
providers
though,
overall,
only
21.5%
having
done
so.
those
who
diagnosis,
modes
eating
food,
smoking,
pills
or
tinctures,
reasons
sleep
disturbance,
followed
pain
anxiety
60%-68%
reporting
improved
symptoms
Conclusion
geographically
diverse
demonstrates
regardless
its
Addressing
knowledge
gaps
concerning
harms
critical
enhance
patient-provider
communication.
Internal Medicine Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 5, 2025
Following
sustained
public
pressure
and
despite
a
paucity
of
evidence
to
support
medical
benefit,
medicinal
cannabis
(MC)
was
legalised
in
Australia
2016
for
use
resistant
childhood
epilepsy,
chemotherapy-induced
nausea
vomiting
(CINV),
spasticity
associated
with
multiple
sclerosis,
chronic
non-cancer
pain
'palliative
care'.1
Over
subsequent
years,
there
has
been
an
exponential
rise
the
number
prescriptions
approved2
'indication
creep'.
Most
common
Special
Access
Scheme
applications
Therapeutic
Goods
Administration
are
pain,
anxiety,
sleep
disorders
cancer
symptoms.3
Popular
brands
include
those
tetrahydrocannabinol
(THC),
most
psychoactive
cannabinoid.
This
is
fact
that
THC
significant
side
effects,
it
illegal
drive
while
taking
states.
Cannabis
remains
popular
amongst
patients.
A
recent
review
reports
one-quarter
adults
receiving
treatment
at
clinic
United
States
had
used
past
30
days
attempt
fight
or
ameliorate
symptoms
related
disease
its
treatment.4
The
reasons
given
by
over
1000
patients
survivors
South
Carolina
were
difficulty
sleeping,
stress/anxiety/depression
pain.5
ongoing
interest
not
surprising
when
uncontrolled
trials
continually
report
benefits,
supported
strong
media
bias
towards
positive
results.6
fake
news
story
claiming
cured
received
100-fold
more
attention
than
evidence-based
debunking
theory.7
much
research
undertaken
answer
many
unknowns
around
(e.g.
what
combination
cannabinoids
best,
dose
schedule)
explore
where
might
be
effective.
Uncontrolled
studies
case
continue
benefit
range
conditions.8
Randomised
controlled
(RCTs)
do
not.9
So,
hard
date
oncology/palliative
care?
There
considerable
vitro
work
pointing
potential
anti-neoplastic
activity
cannabinoids10
but
sparse
clinical
evidence.
Schloss
et
al.
reported
on
safety
quality-of-life
benefits
RCT
two
different
cannabidiol
(CBD)/THC
products.11
small
phase
1b
study
tolerability
nabiximol
dose-intense
temozolamide
relapsed
glioblastoma
confirmed
(1:1
THC/CBD).12
powered
efficacy,
survival
suggests
further
warranted.
Less
well
known
contains
major
carcinogens
tobacco
several
cancers
have
epidemiologically
linked
CBD
exposure.13
American
Society
Clinical
Oncology
guidelines
give
recommendation
against
place
cancer-directed
any
augment
should
done
context
trial.14
cytochrome
P450
system,
specifically
subfamilies
2C,
1A,
3A
2D,
plays
prominent
role
cannabinoid
metabolism.
CYP3A
CYP2C
enzymes
involved
metabolism
prescribed
medications,
creating
opportunity
cannabinoid/drug
interactions.
As
potent
CYP3AA
inhibitor,
example,
increase
levels
ribociclib,
resulting
increased
risk
adverse
effects
women
this
drug
breast
cancer.15
issue
whether
conjunction
immunotherapy
controversial.
Deleterious
respect
response,
time
progression
overall
reported,
cohort
only.16,
17
Pain
one
people
who
take
cannabinoids.
systematic
reviews
mixed
aetiologies
point
questionable
significance.18
It
difficult
demonstrate
pain.
Cochrane
Review
concludes
THC-containing
products
'ineffective
relieving
moderate
severe
opioid
refractory
pain'.9
Multinational
Association
Supportive
Care
Cancer
(MASCC)
guidance
recommends
as
adjuvant
analgesic
harm
events
carefully
considered
all
patients.19
Despite
pre-clinical
data
supporting
opioid-sparing
effect,
very
studies.20
Synthetic
(dronabinol
nabilone)
recognised
years
being
effective
anti-nausea
medications
never
tested
modern
antiemetics.
placebo-controlled
from
Sydney21
followed
promising
II
cross-over
study22
efficacy
low-dose
THC/CBD
CINV
expense
greater
toxicity
(sedation,
dizziness
anxiety).
terminated
early
because
recruitment.
Driving
restrictions
factor,
already
using
aversion
it.
authors
conclude
'drug
availability,
cultural
attitudes,
legal
status
preferences
may
affect
implementation'
future.
MASCC
quotes
insufficient
recommend
management
advanced
cancer,
cancer-associated
anorexia-cachexia
taste
disturbance.23
Very
few
quality
addressed
psychological
(anxiety,
stress
depression)
primary
outcome
measures
patients.24,
25
With
current
evidence,
cannot
recommended
these
likelihood
anxiety
higher-dose
THC.26
Small
demonstrated
cancer.18
MC
palliative
care,26,
27
generally
'nothing
lose'
scenario
rather
shown
benefit.
Our
group
elected
total
symptom
burden
(a
summated
score)
holistic
approach
exploring
cannabis.
We
found
both
alone28
1:1
CBD/THC
oil29
no
better
care
reducing
although
improvement
addition
THC.
Although
tolerated,
commonly
gastrointestinal
(nausea/vomiting,
diarrhoea),
somnolence.18,
26
Concern
raised
regarding
worsening
psychotic
(particularly
THC)
deleterious
effect
liver
function.14
how
dust
settled?
proven
antiemetic
(subject
patient
choice
caveats
toxicity)
help
some
patients'
sleep.
expensive
see
government
subsidy
can
justified
based
knowledge.
At
stage,
clinicians
need
feel
pressured
prescribe,
findings
specialty
society
available
assist
counselling
request
Patients
encouraged
enter
if
available,
prescribing
ensure
follow-up
assessment
and/or
harms.
Cancer Causes & Control,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Abstract
Purpose
There
is
increasing
interest
in
the
use
of
cannabis
products
to
alleviate
symptom
burden
among
cancer
patients.
Although
data
remain
limited,
some
evidence
suggests
that
state
legalization
associated
with
reduced
opioid
use.
Indices
area-level
social
determinants
health
may
provide
insights
into
patterns
symptom-managing
behaviors
context
equity.
Methods
Residential
ZIP
codes
from
854
Ohio
residents
diagnosed
invasive
at
an
academic
center
were
used
assign
rural–urban
commuting
area
(RUCA)
and
deprivation
index
(SDI)
values.
RUCA
was
categorized
as
metropolitan
non-metropolitan,
SDI
dichotomized
median.
Participants
completed
a
one-time
cannabis-focused
questionnaire
which
included
items
on
medications
symptoms.
Results
The
prevalence
self-reported
(19%
vs.
13%)
(30%
21%)
higher
patients
living
areas
disadvantage
lower.
No
differences
observed
for
benzodiazepines
or
any
product
by
residential
urbanicity.
Conclusion
Larger,
multi-institutional
studies
detailed
measurement
increased
capacity
examine
additional
are
needed
confirm
explain
these
descriptive
findings.
World Journal of Critical Care Medicine,
Journal Year:
2025,
Volume and Issue:
14(2)
Published: Feb. 27, 2025
BACKGROUND
The
burden
of
cannabis
use
disorder
(CUD)
in
the
context
its
prevalence
and
subsequent
cardiopulmonary
outcomes
among
cancer
patients
with
severe
sepsis
is
unclear.
AIM
To
address
this
knowledge
gap,
especially
due
to
rising
patterns
emerging
pharmacological
role
cancer.
METHODS
By
applying
relevant
International
Classification
Diseases,
Ninth
Tenth
Revision,
Clinical
Modification
codes
National
Inpatient
Sample
database
between
2016-2020,
we
identified
CUD(+)
CUD(-)
arms
adult
admissions
sepsis.
Comparing
two
cohorts,
examined
baseline
demographic
characteristics,
epidemiological
trends,
major
adverse
cardiac
cerebrovascular
events,
respiratory
failure,
hospital
cost,
length
stay.
We
used
Pearson
χ
2
d
test
for
categorical
variables
Mann-Whitney
U
continuous,
non-normally
distributed
variables.
Multivariable
regression
analysis
was
control
potential
confounders.
A
P
value
≤
0.05
considered
statistical
significance.
RESULTS
a
total
743520
admitted
sepsis,
which
4945
had
CUD.
Demographically,
cohort
more
likely
be
younger
(median
age
=
58
vs
69,
<
0.001),
male
(67.9%
57.2%,
black
(23.7%
14.4%,
Medicaid
enrollees
(35.2%
10.7%,
whom
higher
rates
substance
depression
were
observed.
also
exhibited
chronic
pulmonary
disease
but
lower
cardiovascular
comorbidities.
There
no
significant
difference
events
cohorts
on
multivariable
analysis.
However,
all-cause
mortality
(adjusted
odds
ratio
0.83,
95%
confidence
interval:
0.7-0.97,
0.001)
failure
0.8,
0.69-0.92,
0.002).
Both
groups
similar
median
stay,
though
have
cost
compared
94574
dollars
86615
dollars,
0.001).
CONCLUSION
who
tended
younger,
black,
males
paradoxically
significantly
in-hospital
failure.
Future
research
should
aim
better
elucidate
underlying
mechanisms
these
observations.
JNCI Monographs,
Journal Year:
2024,
Volume and Issue:
2024(66), P. 282 - 289
Published: Aug. 1, 2024
Abstract
Background
The
benefits
of
cannabis
in
symptom
management
among
cancer
survivors
are
widely
acknowledged;
however,
patterns
use
by
stage
at
diagnosis
unknown.
Methods
Here,
we
examined
the
association
between
and
consideration
since
diagnosis.
We
analyzed
cross-sectional
survey
data
from
954
survivors,
weighted
to
be
representative
a
National
Cancer
Institute–Designated
Comprehensive
Center’s
patient
population.
used
survey-weighted
multivariable
logistic
regression
examine
(advanced
[III/IV]
versus
non-advanced
[I/II])
(yes
no)
Results
Sixty
percent
population
was
diagnosed
with
stages
cancer,
42%
had
considered
using
odds
were
63%
higher
(odds
ratio
=
1.63,
95%
confidence
interval
1.06
2.49)
III/IV
than
those
I/II.
Conclusion
may
predictor
after
JNCI Monographs,
Journal Year:
2024,
Volume and Issue:
2024(66), P. 224 - 233
Published: Aug. 1, 2024
Abstract
Background
Although
substance
use
may
have
adverse
impacts
on
cancer
outcomes,
little
is
known
regarding
patterns
of
concurrent
with
cannabis
among
patients.
Our
objective
was
to
examine
predictors
patients
since
their
diagnosis
and
explore
perceptions
these
Methods
Patients
treated
at
a
National
Cancer
Institute–designated
comprehensive
center
were
invited
participate
in
an
electronic
survey
medical
from
August
November
2021.
Survey
data
linked
internal
resources
including
health
records
patient
intake
forms
obtain
history
(defined
as
within
least
3
months
diagnosis)
cigarettes,
injection
drugs,
high
levels
alcohol,
or
clinically
unsupervised
prescription
drugs
(total
n
=
1094).
Concurrent
users
defined
those
any
reported
the
time
diagnosis.
We
used
descriptive
statistics
(χ2
exact
tests)
compare
groups
estimated
adjusted
odds
ratios
(AORs)
95%
confidence
intervals
(CIs)
identify
nonusers
cannabis.
Results
Approximately
45%
(n
489)
sample
Of
who
using
cannabis,
20%
self-reported
polysubstance
use,
while
8%
(P
<
.001).
Among
2
more
treatment-related
symptoms
(eg,
pain,
fatigue)
likely
(AOR
3.15,
CI
1.07
9.27)
compared
without
symptoms.
nonusers,
lower
educational
background
3.74,
1.57
8.92).
report
improved
sleep
.04),
increased
appetite
.03),
treatment
additional
conditions
.04)
perceived
benefits
use.
Conclusions
High
symptom
burden
be
associated
Cancer Epidemiology Biomarkers & Prevention,
Journal Year:
2024,
Volume and Issue:
33(4), P. 600 - 607
Published: Jan. 31, 2024
Abstract
Background:
Alcohol
is
a
risk
factor
for
cancer
and
may
pose
unique
risks
survivors.
Population-based
studies
of
confirmed
cases
are
needed
to
estimate
the
extent
drinking
among
survivors
understand
which
most
at
alcohol-related
health
problems.
Methods:
Cancer
who
resided
in
Puget
Sound
Surveillance,
Epidemiology,
End
Results
(SEER)
region,
were
ages
21
74
years
diagnosis,
6
17
months
post-diagnosis
start
recruitment
period
(April
2020–December
2020)
sent
survey
that
included
demographics,
substance
use,
mental
health,
cancer-related
items.
Data
from
returned
surveys
(n
=
1,488)
weighted
represent
characteristics
SEER
region.
We
estimated
prevalence
alcohol
use
as
well
demographic,
behavioral,
clinical
correlates
three
levels
drinking:
any
drinking,
exceeding
prevention
guidelines,
hazardous
drinking.
Results:
The
was
71%,
46.2%,
31.6%,
respectively.
Higher
income
cannabis
associated
with
increased
odds
all
levels.
Lower
physical
quality
life,
having
non-colorectal
gastrointestinal
cancer,
receiving
chemotherapy
within
last
month
decreased
Conclusions:
at-risk
higher
than
previous
differed
based
on
sociodemographic,
factors.
Impact:
Findings
highlight
importance
identifying
addressing
risky
care
settings.